Melancholic features in major depression - a European multicenter study.


Journal

Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617

Informations de publication

Date de publication:
30 08 2021
Historique:
received: 21 09 2020
revised: 31 01 2021
accepted: 12 02 2021
pubmed: 21 2 2021
medline: 8 2 2022
entrez: 20 2 2021
Statut: ppublish

Résumé

There is still a debate, if melancholic symptoms can be seen rather as a more severe subtype of major depressive disorder (MDD) or as a separate diagnostic entity. The present European multicenter study comprising altogether 1410 MDD in- and outpatients sought to investigate the influence of the presence of melancholic features in MDD patients. Analyses of covariance, chi-squared tests, and binary logistic regression analyses were accomplished to determine differences in socio-demographic and clinical variables between MDD patients with and without melancholia. We found a prevalence rate of 60.71% for melancholic features in MDD. Compared to non-melancholic MDD patients, they were characterized by a significantly higher likelihood for higher weight, unemployment, psychotic features, suicide risk, inpatient treatment, severe depressive symptoms, receiving add-on medication strategies in general, and adjunctive treatment with antidepressants, antipsychotics, benzodiazepine (BZD)/BZD-like drugs, low-potency antipsychotics, and pregabalin in particular. With regard to the antidepressant pharmacotherapy, we found a less frequent prescription of selective serotonin reuptake inhibitors (SSRIs) in melancholic MDD. No significant between-group differences were found for treatment response, non-response, and resistance. In summary, we explored primarily variables to be associated with melancholia which can be regarded as parameters for the presence of severe/difficult-to treat MDD conditions. Even if there is no evidence to realize any specific treatment strategy in melancholic MDD patients, their prescribed medication strategies were different from those for patients without melancholia.

Identifiants

pubmed: 33609603
pii: S0278-5846(21)00044-0
doi: 10.1016/j.pnpbp.2021.110285
pii:
doi:

Substances chimiques

Antidepressive Agents 0
Antipsychotic Agents 0
Serotonin Uptake Inhibitors 0
Benzodiazepines 12794-10-4

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

110285

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Markus Dold (M)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Lucie Bartova (L)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Gernot Fugger (G)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Alexander Kautzky (A)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Marleen M M Mitschek (MMM)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Chiara Fabbri (C)

Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom.

Stuart Montgomery (S)

Imperial College, University of London, London, United Kingdom.

Joseph Zohar (J)

Psychiatric Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Daniel Souery (D)

School of Medicine, Free University of Brussels, Brussels, Belgium; Psy Pluriel - European Centre of Psychological Medicine, Brussels, Belgium.

Julien Mendlewicz (J)

School of Medicine, Free University of Brussels, Brussels, Belgium.

Alessandro Serretti (A)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.

Siegfried Kasper (S)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; Center for Brain Research, Medical University of Vienna, Vienna, Austria. Electronic address: siegfried.kasper@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH